Valuation
- Market cap
- 1,430,411,000
- Revenue TTM
- $9,770,000
- Net income TTM
- $-109,000,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -1,115.66%
- Debt to equity
- 0.23
Trading
- Volume
- 3,912,400
- Avg volume
- 3,319,684
- Day's range
- $4.26 – $4.46
- Shares out
- 325,834,000
- Stochastic %K
- 21%
- Beta
- 1.19
- Analysts
- Strong Sell
- Price target
- $13.00
Company profile
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for...
Show more
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 214 612 0000
- Website
- https://www.tayshagtx.com
- Address
- 3000 Pegasus Park Drive, Suite 1430, Dallas, United States
Latest news
No headlines yet.
